Gryphon Therapeutics, Inc.

Gryphon Sciences

Jill Wilken

Robin E Offord

Darren Thompson

Stephen B H Kent

Reyna J Simon

Michael A Siani

N-terminally modified RANTES derivatives are disclosed. The derivatives effectively block the inflammatory effects of RANTES, and are useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma/atherosclerosis, and rheumatoid arthritis. Additionally, the compounds are useful for the treatment of HIV infection.

N-terminal modifications of RANTES and methods of use

Novel proteins and protein libraries are disclosed. The proteins possess one or more functional protein modules from different parent protein molecules. The proteins and protein libraries are exemplified by the preparation of cross-over chemokines that contain various combinations of peptide segments derived from RANTES, SDS-1 and vMIP-I and to vMIP-II. The proteins and libraries are extremely pure and can be provided in non-limiting high yields suitable for diagnostic and high-throughput screening assays.

Modular protein libraries and methods of preparation

Growing community of inventors

San Francisco, CA, United States of America

Jill Wilken